TP53 and neoplasm: The analysis of paired blood-tumor samples from MSK-IMPACT revealed that of 17,992 patients with solid malignancies only 50 (0.28%) individuals had TP53 mutations, with only 38 (0.19%) confirmed to be of germline origin.